Kodiak Sciences Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical inflection point, where the transition from clinical development to commercialization is fraught with high-stakes binary risks. The bull case is built on the architectural superiority of the ABC platform and a meticulously prepared financial and manufacturing foundation. Conversely, the bear case highlights a track record of clinical misses and a balance sheet that is under significant pressure from a high burn rate and fixed obligations. Ultimately, the investment thesis hinges on the 3Q 2026 DAYBREAK topline data. A success here would validate the enhanced formulation and the 'treat-to-dryness' protocol, potentially unlocking the asymmetric upside of the company's commercial readiness. However, any further clinical setbacks or safety concerns would likely render the company's sophisticated financial engineering irrelevant, as the market would price in the high likelihood of continued dilution or insolvency.